Risk Stratification of Pancreatic Ductal Adenocarcinoma Patients Undergoing Curative-Intent Surgery after Neoadjuvant Therapy

被引:1
|
作者
Yang, Hyun Kyung [1 ]
Park, Mi-Suk [1 ]
Han, Kyunghwa [2 ,3 ]
Eom, Geonsik [4 ]
Chung, Yong Eun [1 ]
Choi, Jin-Young [1 ]
Bang, Seungmin [5 ]
Kang, Chang Moo [6 ]
Seong, Jinsil [7 ]
Kim, Myeong-Jin [1 ]
机构
[1] Yonsei Univ, Severance Hosp, Dept Radiol, Coll Med, Seoul, South Korea
[2] Yonsei Univ, Res Inst Radiol Sci, Dept Radiol, Coll Med, Seoul, South Korea
[3] Yonsei Univ, Ctr Clin Imaging Data Sci, Coll Med, Seoul, South Korea
[4] Yonsei Univ, Dept Med, Coll Med, Seoul, South Korea
[5] Yonsei Univ, Severance Hosp, Inst Gastroenterol, Dept Internal Med,Coll Med, Seoul, South Korea
[6] Yonsei Univ, Severance Hosp, Pancreatobiliary Canc Ctr, Yonsei Canc Ctr,Dept Surg,Coll Med, Seoul, South Korea
[7] Yonsei Univ, Severance Hosp, Dept Radiat Oncol, Coll Med, Seoul, South Korea
来源
CANCER RESEARCH AND TREATMENT | 2024年 / 56卷 / 01期
关键词
Pancreatic ductal carcinoma; Prognosis; Neoadjuvant therapy; X-ray computed tomography; CA-19-9; antigen; CONSENSUS STATEMENT; CANCER; LEWIS; CHEMOTHERAPY; RESECTION; TUMOR; PHENOTYPE; CA19-9; SERUM;
D O I
10.4143/crt.2023.586
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose Clinical prognostic criteria using preoperative factors were not developed for post-neoadjuvant therapy (NAT) surgery of pancreatic ductal adenocarcinoma (PDAC). We aimed to identify preoperative factors associated with overall survival (OS) in PDAC patients who underwent post-NAT curative-intent surgery and develop risk stratification criteria. Materials and Methods Consecutive PDAC patients who underwent post-NAT curative-intent surgeries between 2007 and 2020 were retrospectively analyzed. Demographic, laboratory, surgical, and histopathologic variables were collected. Baseline, preoperative, and interval changes of computed tomography (CT) findings proposed by the Society of Abdominal Radiology and the American Pancreatic Association were analyzed. Cox proportional hazard analysis was used to select preoperative variables associated with OS. We developed risk stratification criteria composed of the significant preoperative variables, i.e., post-NAT response criteria. We compared the discrimination performance of post-NAT response criteria with that of post-NAT pathological (yp) American Joint Cancer Committee TNM staging system. Results One hundred forty-five PDAC patients were included. Stable or increased tumor size on CT (hazard ratio [HR], 2.58; 95% confidence interval [CI], 1.58 to 4.21; p < 0.001) and elevated preoperative carbohydrate antigen 19-9 (CA19-9) level (HR, 1.98; 95% CI, 1.11 to 3.55; p=0.021) were independent factors of OS. The OS of the patient groups stratified by post-NAT response criteria which combined changes in tumor size and CA19-9 showed significant difference (p < 0.001). Such stratification was comparable to ypTNM staging in discrimination performance (difference of C-index, 0.068; 95% CI, -0.012 to 0.142). Conclusion "Any degree of decrease in tumor size on CT" and CA19-9 normalization or staying normal were independent favorable factors of OS. The combination of the two factors discriminated OS comparably to ypTNM staging.
引用
收藏
页码:247 / 258
页数:12
相关论文
共 50 条
  • [21] Survival outcomes of conversion surgery for metastatic pancreatic ductal adenocarcinoma after neoadjuvant therapy
    Zhu Lingyu
    Gao Suizhi
    Wu Xinqian
    Li Bo
    Shi Xiaohan
    Yin Xiaoyi
    Wang Huan
    Shi Meilong
    Li Penghao
    Li Yikai
    Zhong Chaoliang
    Teng Chuanqi
    Han Jiawei
    Ren Yiwei
    Wang Jian
    Fu Zhendong
    Liu Xinyu
    Zheng Kailian
    Guo Shiwei
    Jin Gang
    胰腺病学杂志(英文), 2023, 06 (03)
  • [22] Improving patient stratification and selection for curative-intent treatment in localized pancreatic cancer
    Martos, Mary P.
    Amirian, Haleh
    Merchant, Nipun B.
    Hosein, Peter J.
    Hester, Caitlin A.
    Datta, Jashodeep
    HEPATOBILIARY SURGERY AND NUTRITION, 2024, 13 (02) : 325 - 328
  • [23] Recurrence patterns and postrecurrence survival after curative intent resection for pancreatic ductal adenocarcinoma
    Kolbeinsson, Hordur
    Hoppe, Allison
    Bayat, Aqieda
    Kogelschatz, Benjamin
    Mbanugo, Chineze
    Chung, Mathew
    Wolf, Andrea
    Assifi, M. Mura
    Wright, G. Paul
    SURGERY, 2021, 169 (03) : 649 - 654
  • [24] Plasma Extracellular Vesicle Characteristics Correlate with Tumor Differentiation and Predict Overall Survival in Patients with Pancreatic Ductal Adenocarcinoma Undergoing Surgery with Curative Intent
    Badovinac, David
    Goricar, Katja
    Zavrtanik, Hana
    Petric, Miha
    Lavrin, Teja
    Mavec, Nina
    Dolzan, Vita
    Tomazic, Ales
    Lenassi, Metka
    JOURNAL OF PERSONALIZED MEDICINE, 2021, 11 (02): : 1 - 12
  • [25] Risk Factors Associated With Early Recurrence of Borderline Resectable Pancreatic Ductal Adenocarcinoma After Neoadjuvant Chemoradiation Therapy and Curative Resection
    Tsuchiya, Nobuhiro
    Matsuyama, Ryusei
    Murakami, Takashi
    Yabushita, Yasuhiro
    Sawada, Yu
    Kumamoto, Takafumi
    Endo, Itaru
    ANTICANCER RESEARCH, 2019, 39 (08) : 4431 - 4440
  • [26] Development and Validation of a Predictive Risk Score for Blood Transfusion in Patients Undergoing Curative-Intent Surgery for Intrahepatic Cholangiocarcinoma
    Catalano, Giovanni
    Alaimo, Laura
    Endo, Yutaka
    Chatzipanagiotou, Odysseas P.
    Ruzzenente, Andrea
    Aldrighetti, Luca
    Weiss, Matthew
    Bauer, Todd W.
    Alexandrescu, Sorin
    Poultsides, George A.
    Maithel, Shishir K.
    Marques, Hugo P.
    Martel, Guillaume
    Pulitano, Carlo
    Shen, Feng
    Cauchy, Francois
    Koerkamp, Bas G.
    Endo, Itaru
    Kitago, Minoru
    Pawlik, Timothy M.
    JOURNAL OF SURGICAL ONCOLOGY, 2024,
  • [27] Neoadjuvant therapy in pancreatic ductal adenocarcinoma: A competing risk analysis
    Pacilio, Carlo Alberto
    Grassi, Elisa
    Gardini, Andrea
    Fappiano, Francesca
    Passardi, Alessandro
    Frassineti, Giovanni Luca
    Tamberi, Stefano
    Ercolani, Giorgio
    SURGICAL PRACTICE, 2022, 26 (03) : 155 - 164
  • [28] Pancreatic ductal adenocarcinoma after neoadjuvant therapy: Histomorphologic characterisation
    Haeberle, L.
    Kapp, A. -C.
    Esposito, I.
    VIRCHOWS ARCHIV, 2017, 471 : S130 - S130
  • [29] Sarcopenia in Patients Undergoing Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma: Can Surgical Resection Be Predicted?
    Davis, Catherine H.
    Beier, Matthew
    Aslam, Anum
    Grandhi, Miral S.
    Kennedy, Timothy J.
    August, David A.
    Ecker, Brett L.
    Bramwit, Mark
    Langan, Russell C.
    Pitt, Henry A.
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2023, 237 (05) : S476 - S477
  • [30] Patient surveillance after curative-intent surgery for rectal cancer
    Johnson, FE
    Longo, WE
    Ode, K
    Shariff, US
    Papettas, T
    McGarry, AE
    Gammon, SR
    Lee, PA
    Audisio, RA
    Grossmann, EM
    Virgo, KS
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2005, 27 (03) : 815 - 822